	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	0.14	0.09	0.41	0.39	0.19	0.74	1.26	1.21	2.78	3.83
Cost of Operating Revenue	0.10	0.09	0.13	0.35	0.31	0.61	1.04	1.02	2.02	2.71
Gross Profit	0.04	-0.01	0.28	0.05	-0.12	0.13	0.22	0.18	0.76	1.12
Gross Margin	28.3	-7.9	69.3	12.2	-64.4	17.2	17.4	15.3	27.2	29.2
Total Operating Expenses	0.15	0.10	0.22	0.63	0.61	1.01	1.69	1.62	3.07	4.12
Operating Profit	-0.01	-0.02	0.19	-0.23	-0.43	-0.27	-0.43	-0.41	-0.29	-0.29
Operating Margin	-8.3	-19.3	47.1	-59.1	-226.8	-36.7	-34.4	-34.0	-10.5	-7.6
Financing Income/(Expense) - Net	0.01	0.02	0.00	-0.01	0.00	0.00	-0.02	-0.03	-0.07	-0.09
Profit before Taxes	0.00	0.00	0.30	0.03	0.02	-0.26	0.04	0.05	0.11	0.11
Income Taxes	0.01	0.00	0.08	0.03	0.00	-0.03	0.00	0.02	0.03	0.04
Profit after Tax	0.00	0.00	0.22	-0.01	0.01	-0.23	0.04	0.03	0.08	0.07
PAT Margin	-2.2	1.0	53.6	-2.0	6.3	-30.8	2.9	2.4	2.9	1.9
EPS - Basic - ex Extraordinary Items	-0.01	0.00	0.45	-0.02	0.02	-0.47	0.08	0.06	0.17	0.17
EPS - Diluted - ex Extraordinary Items	-0.01	0.00	0.45	-0.02	0.02	-0.47	0.08	0.05	0.14	0.17
EBIT	-0.01	-0.02	0.19	-0.23	-0.43	-0.27	-0.43	-0.41	-0.29	-0.29
EBITDA	0.06	0.05	0.29	-0.14	-0.33	-0.19	-0.35	-0.33	-0.13	-0.10
EBITDA Margin	41.6	59.0	70.5	-34.9	-175.5	-25.0	-27.6	-27.3	-4.7	-2.7

Balance Sheet

Abridged

Understanding Balance Sheet

Novateor Research Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	0.23	0.24	0.76	5.14	5.49	6.10	6.49	7.52	9.14	10.95
Long-Term Investments	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Property Plant & Equipment - Net	1.66	1.59	3.55	3.45	3.36	1.94	2.21	2.87	3.41	3.24
Total Non-Current Assets	1.67	1.60	3.56	3.65	3.49	2.04	2.46	2.94	3.48	3.31
Total Assets	1.90	1.84	4.32	8.79	8.97	8.14	8.95	10.46	12.61	14.26
Total Current Liabilities	0.12	0.09	0.22	0.05	0.11	0.05	0.73	1.20	1.63	2.39
Long Term Debt	0.84	0.82	0.01	0.14	0.24	0.24	0.33	0.47	0.41	0.32
Total Non-Current Liabilities	0.85	0.82	0.02	0.18	0.29	0.25	0.34	0.50	0.44	0.37
Total Liabilities	0.97	0.91	0.24	0.23	0.40	0.30	1.07	1.70	2.07	2.76
Total Shareholders' Equity	0.93	0.93	4.08	8.56	8.57	7.84	7.88	8.76	10.54	11.50
Total Equity	0.93	0.93	4.08	8.56	8.57	7.84	7.88	8.76	10.54	11.50
Total Liabilities & Equity	1.90	1.84	4.32	8.79	8.97	8.14	8.95	10.46	12.61	14.26

Cash Flow

Abridged

Understanding Cash Flow Statement

Novateor Research Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	0.07	0.07	0.32	0.13	0.29	0.03	0.13	0.13	0.27	0.30
Working Capital - Increase/(Decrease)	-0.07	-0.02	-0.39	-3.54	-0.40	-1.21	-0.62	-0.65	-0.90	-1.05
Net CF from Operating Activities	0.00	0.05	-0.08	-3.41	-0.12	-1.18	-0.50	-0.52	-0.62	-0.75
Capital Expenditures - Net	0.01	-	1.96	0.10	0.09	1.51	0.36	0.74	0.70	0.02
Net CF from Investing Activities	-0.01	-	-1.96	-0.10	-0.09	-1.51	-0.36	-0.74	-0.70	-0.02
Stock - Issuance/(Retirement) - Net	-	-	2.84	4.49	-	-	-	0.85	1.70	0.86
Debt - LT & ST - Issuance/(Retirement) - Total	0.01	-0.03	-0.80	-0.32	0.18	0.21	0.60	0.27	-0.20	0.11
Net Cash Flow from Financing Activities	0.01	-0.03	2.03	4.17	0.18	0.21	0.60	1.13	1.50	0.97
Free Cash Flow to Equity	-0.01	0.02	-2.84	-3.83	-0.03	-2.48	-0.25	-0.99	-1.52	-0.66
Free Operating CF net dividend	-0.02	0.05	-2.04	-3.51	-0.21	-2.69	-0.85	-1.26	-1.32	-0.77
Free Operating CF	-0.02	0.05	-2.04	-3.51	-0.21	-2.69	-0.85	-1.26	-1.32	-0.77

Business Segment Analysis

Novateor Research Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Novateor Research Laboratories Ltd.

Regional Segment Analysis

Novateor Research Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Novateor Research Laboratories Ltd.

Historical Segment Analysis

Track how Novateor Research Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Novateor Research Laboratories Ltd.

Frequently Asked Questions

What is the revenue of Novateor Research Laboratories Ltd.?

The latest trailing twelve month revenue of Novateor Research Laboratories Ltd. is ₹ 3.83 Cr, reflecting a 1-year growth of 37.81% and a 3-year CAGR of 44.82%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Novateor Research Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Novateor Research Laboratories Ltd. is ₹ 0.07 Cr, with a 3-year earnings CAGR of 28.56%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Novateor Research Laboratories Ltd.?

The trailing twelve month EBITDA of Novateor Research Laboratories Ltd. is approximately ₹ -0.29 Cr (based on an operating margin of -7.57%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Novateor Research Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Novateor Research Laboratories Ltd. is 0.17. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Novateor Research Laboratories Ltd.?

The debt-to-equity ratio of Novateor Research Laboratories Ltd. stands at 0.09. The interest coverage ratio is -3.38x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Novateor Research Laboratories Ltd.?

The estimated book value per share of Novateor Research Laboratories Ltd. is 17.42 (derived from a P/B ratio of 1.89 and market price of ₹ 32.85), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Novateor Research Laboratories Ltd.?

The trailing twelve month operating cash flow of Novateor Research Laboratories Ltd. is ₹ -0.75 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Novateor Research Laboratories Ltd. report consolidated or standalone financials?

Novateor Research Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.